Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Newron Pharmaceuticals SpA    NWRN   IT0004147952

Delayed Quote. Delayed  - 09/27 05:30:11 pm
22.15 CHF   -1.56%
09/22 Newron re-submits US NDA for Xadago® (safinamide)
09/22 NEWRON PHARMACE : Re-Submits US NDA for Xadago® (Safinamide)
09/15 Newron reports half-year 2016 results
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Newron Pharmaceuticals SpA
Discovers and develops small molecule drugs

Newron Pharmaceuticals SpA is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the Central Nervous System (CNS) and pain.

The focus of its treatments includes patients with Parkinson's disease, Rett Syndrome, Amyotrophic Lateral Sclerosis, schizoprenia, and neuropathic pain.

The company was founded by Luca Benatti, Ruggero Fariello, and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Number of employees : 23 persons.
Sales per Businesses
20142015Delta
CHF (in Million)%CHF (in Million)%
Pharmaceutical Drugs1.58100%1.9279.1% +21.76%
Sales per Regions
20142015Delta
CHF (in Million)%CHF (in Million)%
Global1.58100%1.9279.1% +21.76%
Managers
NameAgeSinceTitle
Stefan Weber512005Chief Executive Officer, Director & IR Contact
Ulrich Köstlin, PhD642013Non-Executive Chairman
Roberto Galli-2002Vice President-Finance
Ravi Anand, MD592005Chief Medical Officer
Patrick J. Langlois, PhD712008Independent Non-Executive Director
Robert Leslie Holland MD, PhD612013Independent Non-Executive Director
Bo Jesper Hansen MD, PhD582013Independent Non-Executive Director
Joseph Donald deBethizy, PhD652014Independent Non-Executive Director
Luca Benatti, PhD552014Independent Non-Executive Director
Marco Caremi592002Executive Vice President-Business Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 14,448,638 10,211,200 70.7% 0 0.0% 70.7%
Shareholders
NameEquities%
Investor AB 1,772,817 12.3%
Gefim SpA 1,311,957 9.08%
Aviva Plc 1,307,550 9.05%
JPMorgan Asset Management (UK) Ltd. 309,630 2.14%
UBS AG (Investment Management) 231,094 1.60%
Polar Capital LLP 150,334 1.04%
Union Investment Privatfonds GmbH 149,140 1.03%
Aviva Investors Global Services Ltd. 127,637 0.88%
Credit Suisse AG 100,396 0.69%
BlackRock Fund Advisors 49,311 0.34%
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Advertisement
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
NEWRON PHARMACEUTICALS..-10.74%335
AMGEN, INC.6.90%129 863
GILEAD SCIENCES, INC.-20.33%106 391
CELGENE CORPORATION-11.23%82 402
REGENERON PHARMACEUTIC..-25.56%42 552
VERTEX PHARMACEUTICALS..-29.83%21 876
ACTELION LTD21.56%18 591
MEDIVATION INC68.43%13 510
GENMAB A/S24.58%10 299
TESARO INC106.08%5 538
HUALAN BIOLOGICAL ENGI..--.--%5 022
TONGHUA DONGBAO PHARMA..-83.36%4 693
NEUROCRINE BIOSCIENCES..-5.87%4 620
INTERCEPT PHARMACEUTIC..11.16%4 105
EXELIXIS, INC.171.45%3 526
BEIJING SL PHARMACEUTI..--.--%3 365
CHINA BIOLOGIC PRODUCT..-15.11%3 252
SAREPTA THERAPEUTICS I..54.64%3 155
JUNO THERAPEUTICS INC-32.57%3 136
GW PHARMACEUTICALS PLC99.24%3 094
PEPTIDREAM INC38.80%2 952
Sector Bio Therapeutic Drugs
Newron Pharmaceuticals SpA : Connections
DFC Langlois
Oxford Gene Technology IP Ltd.
White City Consulting ApS
Early Clinical Development Consulting Ltd.
Constantia Flexibles Group GmbH
European School of Management & Technology GmbH
Karolinska Development AB (Private Equity)
Assobiotec
PJL Consulting
Wellington Partners GmbH
NOXXON Pharma AG
Italian Angels For Biotech
Constantia Flexibles AG
CMC Contrast AB
EryDel SpA
MipSalus ApS
Universitätsklinikum Würzburg
Orphazyme ApS
The European Association for Bioindustries
Company contact information
Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso, Milan 20091

Phone : +39.02.610.3461
Fax : +39.02.610.34654
Web : www.newron.com
© 2016 People , Fundamentals and Ownership